In a patient with a lower‑back boil who has been on trimethoprim‑sulfamethoxazole (Bactrim DS) since [DATE] and whose wound culture grew MRSA susceptible to Bactrim and E. coli resistant to Bactrim but susceptible to amoxicillin‑clavulanate (Augmentin), should we continue Bactrim alone or add Augmentin for E. coli coverage while assessing wound drainage and clinical improvement?

Recommendation for Polymicrobial Lower-Back Boil with MRSA and E. coli

Continue Bactrim DS alone and focus on aggressive wound drainage and debridement rather than adding Augmentin for E. coli coverage. The MRSA is the clinically dominant pathogen in this skin and soft tissue infection, and incision and drainage is the primary treatment.

Clinical Reasoning

Primary Pathogen Identification

In purulent skin and soft tissue infections like boils (abscesses), MRSA is the predominant pathogen requiring targeted therapy 1, 2, 1. The IDSA guidelines explicitly state that for outpatients with purulent cellulitis or abscesses, empirical therapy for CA-MRSA is recommended, while empirical therapy for other organisms like β-hemolytic streptococci is "likely to be unnecessary" 1, 2, 1. This principle extends to polymicrobial cultures where MRSA is present.

Role of E. coli in Skin Abscesses

E. coli is an uncommon pathogen in simple cutaneous abscesses and is typically not a primary driver of infection in this anatomic location. When E. coli appears in wound cultures from skin abscesses, it often represents:

• Colonization rather than true infection
• Contamination from adjacent areas
• A secondary or bystander organism

The clinical significance of E. coli in this context is questionable, particularly when MRSA—a known aggressive skin pathogen—is also present and susceptible to current therapy.

Surgical Management Takes Priority

The IDSA guidelines are unequivocal: "For a cutaneous abscess, incision and drainage is the primary treatment" 1, 2, 1, 2. The guidelines further state that "for simple abscesses or boils, incision and drainage alone is likely to be adequate" 1.

Antibiotic therapy is recommended for abscesses only when associated with:

• Severe or extensive disease involving multiple sites
• Rapid progression with associated cellulitis
• Signs of systemic illness
• Immunosuppression or comorbidities
• Difficult-to-drain locations (face, hand, genitalia)
• Lack of response to incision and drainage alone 1, 2, 1, 2

Bactrim Monotherapy is Guideline-Concordant

Trimethoprim-sulfamethoxazole (Bactrim) is explicitly recommended as first-line oral therapy for CA-MRSA skin and soft tissue infections 1, 2, 1, 2. The guidelines state: "For empirical coverage of CA-MRSA in outpatients with SSTI, oral antibiotic options include: clindamycin (A-II), trimethoprim-sulfamethoxazole (TMP-SMX) (A-II), a tetracycline (doxycycline or minocycline) (A-II), and linezolid (A-II)" 1, 2, 1, 2.

When dual coverage is needed (for both β-hemolytic streptococci and CA-MRSA), the guidelines recommend "TMP-SMX or a tetracycline in combination with a β-lactam (eg, amoxicillin)" 1, 2. However, this recommendation is for streptococcal coverage, not gram-negative coverage, and applies to non-purulent cellulitis scenarios.

Clinical Assessment Strategy

Monitor for These Specific Indicators of Treatment Failure:

1. Systemic signs: Temperature >38.5°C, heart rate >110 bpm, hypotension
2. Local progression: Expanding erythema beyond 5 cm from wound margins, increasing warmth, worsening purulent drainage
3. Lack of improvement: No reduction in abscess size or pain after 48-72 hours of drainage and antibiotics
4. New lesions: Development of satellite abscesses or new sites of infection

Reassess Need for Drainage

• Ensure complete incision and drainage has been performed
• Consider repeat drainage if fluid reaccumulates
• Evaluate for undrained pockets or loculations
• Assess wound care adequacy (dressing changes, keeping covered) 1

When to Consider Adding or Changing Antibiotics

Add Augmentin or broaden coverage ONLY if:

1. Clinical deterioration occurs despite adequate drainage and Bactrim therapy
2. Signs of deeper soft tissue infection develop (necrotizing fasciitis, myositis)
3. Systemic toxicity emerges (sepsis, bacteremia)
4. The wound is in proximity to the perineum/perianal area where enteric organisms are more likely to be true pathogens

Switch from Bactrim if:

• Repeat cultures grow MRSA resistant to Bactrim
• Clinical failure after 48-72 hours with confirmed adequate drainage
• Patient develops adverse reactions to sulfonamides 3

Important Caveats

Bactrim Limitations

Bactrim has no activity against E. coli in this isolate (confirmed resistant), but this is clinically acceptable given E. coli's questionable role in simple skin abscesses 3. However, be aware that Bactrim also lacks activity against β-hemolytic streptococci, so if the clinical picture suggests streptococcal involvement (rapidly spreading erythema without purulence), reconsider the antibiotic choice 2.

Duration of Therapy

5-10 days of therapy is recommended but should be individualized based on clinical response 1, 2, 1. If the patient shows rapid improvement with drainage, shorter courses may suffice.

Avoid Unnecessary Polypharmacy

Adding Augmentin creates unnecessary antibiotic exposure, increases cost, raises the risk of adverse effects (particularly diarrhea and Clostridioides difficile infection), and promotes antimicrobial resistance without clear clinical benefit 4. The principle of antibiotic stewardship supports treating the clinically relevant pathogen (MRSA) rather than all organisms in a culture.

Summary Algorithm

1. Ensure adequate surgical drainage (primary treatment)
2. Continue Bactrim DS for MRSA coverage
3. Reassess at 48-72 hours for clinical improvement
4. If improving: Complete 5-10 day course
5. If not improving:
   • First, ensure drainage is adequate (repeat if needed)
   • Then consider broadening antibiotics or switching based on repeat cultures
6. Monitor for systemic signs requiring hospitalization or IV therapy

1, 2, 1, 2